

## Special Issue

# Extracellular Vesicle-Based Vaccines

### Message from the Guest Editors

We are slowly progressing from a pandemic to the “new normal” that came about due to the help of novel vaccine technologies. We would like to invite you to share your ideas concerning recent developments that came about during this period focusing on extracellular vesicles (membranous and non-membranous nanovesicles), viral particles, and synthetic particles able to elicit a preventive immune response. In this Special Issue, we will bundle studies and reviews that elucidate the use of extracellular vesicles for vaccination purposes, focusing on their use as a multicargo carrier that will be important in the development of next-generation vaccines.

---

### Guest Editors

Dr. Koen Breyne

Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA

Dr. Taral Rameshchand Lunavat

1. Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA

2. Department of Biomedicine, University of Bergen, 5019 Bergen, Norway

---

### Deadline for manuscript submissions

closed (1 September 2022)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/115520](https://mdpi.com/si/115520)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).